3 results match your criteria: "Laboratoire de Cytogénétique Hématologique CHU Timone Aix Marseille University[Affiliation]"
Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).
Curr Res Transl Med
December 2023
Univ Brest, Inserm, EFS, UMR 1078, GGB, Brest F-29200, France; CHRU Brest, Laboratoire de Génétique Chromosomique, Service de génétique, Brest, France. Electronic address:
Article Synopsis
- - Myelodysplastic neoplasms (MDS) are blood disorders often linked to chromosomal abnormalities, with 40-45% of cases showing these changes at diagnosis and up to 80% in post-treatment MDS.
- - Recent changes in classifications by the WHO and ICC have introduced a new entity focusing on biallelic TP53 inactivation, which necessitates detailed genetic investigations, particularly on the TP53 locus.
- - While molecular features are becoming more essential for diagnosing and prognosing MDS, traditional cytogenetics—including karyotyping—remains crucial, and new scoring systems have been developed combining genetic mutations with established cytogenetic parameters.
The 5th edition of the WHO classification of haematolymphoid tumors: comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Leukemia
April 2023
Laboratoire de Génétique des Hémopathies - CHU GRENOBLE, 38043, Grenoble Cedex 09, France.